Target‐Engagement Prediction From Molecular Structure, In Vitro and Animal Data: A Tutorial for Early Assessment of Clinical Drug Exposure and Therapeutic/Adverse Potential Using the ANDROMEDA and PLATO Software on the InSilicoTrials Platform [PDF]
ABSTRACT The target‐engagement predictor, implemented within the InSilicoTrials cloud‐based, AI‐powered platform for model‐informed drug discovery and development, enables early exploration of time‐dependent pharmacological responses. Predictions can be generated using inputs ranging from molecular structure to in vitro, animal, and clinical data ...
Niccolò Totis +16 more
wiley +2 more sources
Learning Objectives After completing this course, the reader will be able to: Enumerate the clinical indications for sorafenib and sunitinib therapy.Describe the mechanism of action and the pharmacokinetics of sorafenib and sunitinib.Analyze the toxicity profile and appraise the therapeutic effects associated with sorafenib and sunitinib.
AeRang, Kim +2 more
openaire +2 more sources
Plasma N-Terminal Pro-Brain Natriuretic Peptide as Prognostic Marker in Fatal Cardial Decompensation with Sunitinib Malate Therapy [PDF]
A 74-year-old man with metastatic renal cell carcinoma and a history of cardiac failure was treated with sunitinib malate. MUGA echocardiography could not detect a relevant change in the ejection fraction although the clinical situation of the patient ...
Stief, Christian G. +4 more
core +1 more source
5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus sunitinib or bevacizumab as first-line treatment for metastatic colorectal cancer: a randomized Phase IIb study [PDF]
BACKGROUND: Sunitinib is an oral inhibitor of tyrosine kinase receptors implicated in tumor proliferation, angiogenesis, and metastasis. In this randomized, multicenter, open-label Phase IIb study, sunitinib plus mFOLFOX6 (oxaliplatin plus leucovorin ...
Welslau, Manfred +17 more
core +2 more sources
ПРАКТИЧЕСКИЕ РЕКОМЕНДАЦИИ ПО ПРЕДОТВРАЩЕНИЮ И КОРРЕКЦИИ ПОБОЧНЫХ ЭФФЕКТОВ СУНИТИНИБА [PDF]
At present Sunitinib is the drug of choice in the treatment of metastatic renal cell carcinoma. In some cases complications due to the use of the drug make it to be unreasonably discontinued, which potentially affects the results of therapy.
S. L. Gutorov +5 more
core +1 more source
Association of toxicity of sorafenib and sunitinib for human keratinocytes with inhibition of signal transduction and activator of transcription 3 (STAT3). [PDF]
Hand-foot skin reaction is a most common multi-kinase inhibitor-related adverse event. This study aimed to examine whether the toxicity of sorafenib and sunitinib for human keratinocytes was associated with inhibiting signal transduction and activator of
Kazuhiro Yamamoto +12 more
doaj +1 more source
BackgroundPercutaneous cryoablation (PCA) has emerged as an alternative to extirpative management of small renal masses in select patients. In recent years, the use of targeted therapies has become mainstream, while the role of PCA in treating primary ...
Cheng-Yuan Gu +9 more
doaj +1 more source
Sunitinib-induced cardiac hypertrophy and the endothelin axis
International audienceAnti-angiogenics drugs in clinical use for cancer treatment induce cardiotoxic side effects. The endothelin axis is involved in hypertension and cardiac remodelling, and addition of an endothelin receptor antagonist to the anti ...
Viel, Thomas +27 more
core +1 more source
Renal Soluble Guanylate Cyclase Is Downregulated in Sunitinib‐Induced Hypertension
Background The tyrosine kinase inhibitor sunitinib causes hypertension associated with reduced nitric oxide (NO) availability, elevated renal vascular resistance, and decreased fractional sodium excretion.
Jeannine Witte +6 more
doaj +1 more source
Sunitinib Does Not Accelerate Tumor Growth in Patients with Metastatic Renal Cell Carcinoma
Preclinical studies have suggested that sunitinib accelerates metastases in animals, ascribing this to inhibition of the vascular endothelial growth factor receptor or the tumor’s adaptation.
Krastan B. Blagoev +5 more
doaj +1 more source

